Skip to Content

Join the 'Jardiance' group to help and get support from people like you.

Jardiance News

Have Type 2 Diabetes? Try Walking After Eating

Posted 18 Oct 2016 by Drugs.com

TUESDAY, Oct. 18, 2016 – For people with type 2 diabetes, a short walk after eating may help lower blood sugar levels more than exercising at other times of the day, a new study shows. A measurement of blood sugar called postprandial glycemia, which has been linked with heart disease risk, averaged 12 percent lower when study participants took a walk after eating, compared with those who exercised at other times. The largest drop in postprandial glycemia, 22 percent, was achieved by walking after dinner, the study authors found. "If you have type 2 diabetes, there is a guideline to be active for at least 150 minutes a week," said study author Andrew Reynolds, a researcher at the University of Otago, in New Zealand. But, he added, "the benefits we observed due to physical activity after meals suggest that current guidelines should be amended to specify after-meal activity, particularly ... Read more

Related support groups: Diabetes, Type 2, Heart Disease, Glipizide, Insulin Resistance, Glyburide, Invokana, Actos, Pre-Diabetes, Glimepiride, Amaryl, Pioglitazone, Diabetes Mellitus, Avandia, GlipiZIDE XL, Glucotrol, Farxiga, Jardiance, Acarbose, Glucotrol XL, Ischemic Heart Disease

Intensive Type 2 Diabetes Treatment Can Extend Survival: Study

Posted 8 Sep 2016 by Drugs.com

WEDNESDAY, Sept. 7, 2016 – Intensive management of type 2 diabetes can make a difference in how long and how well you live, even if you don't start until middle age, researchers report. People who were already at risk of type 2 diabetes complications were randomly selected to continue with their normal treatment or to be placed in an aggressive and multipronged treatment group. Two decades after the study began, the researchers found that people in the aggressive treatment group lived almost eight years longer. Not only that, they lived better – their risk of heart disease, kidney disease and blindness all dropped. The only complication that didn't seem to improve was nerve damage caused by diabetes. "Early, intensified intervention in type 2 diabetes patients with microalbuminuria with both target-driven pharmacological (medication) and behavioral actions increased life span. And, ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Lantus, Januvia, Glucophage, Novolog, Glipizide, Humalog, Janumet, Byetta, Glyburide, Saxenda, Bydureon, Lantus Solostar, Invokana, Levemir, Actos, Glimepiride

Intensive Blood Sugar Control May Be Too Much for Some With Type 2 Diabetes

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – Intensive treatment of blood sugar levels in some people with type 2 diabetes may cause serious complications, new research suggests. "In this study, we found that, particularly among older patients and patients with serious chronic conditions, intensive treatment nearly doubled the risk of severe hypoglycemia requiring medical attention, including hospitalization," said lead author Dr. Rozalina McCoy. She is an endocrinologist at the Mayo Clinic in Rochester, Minn. Hypoglycemia (low blood sugar) is a serious potential complication of diabetes treatment. The researchers said it can worsen quality of life and has been linked with cardiovascular events, dementia and death. The researchers reviewed information from more than 31,500 American adults. All had stable and controlled type 2 diabetes. None was taking insulin. None had a prior history of severe ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Dementia, Lantus, Glucophage, Novolog, Glipizide, Humalog, Hypoglycemia, Janumet, Glyburide, Lantus Solostar, Invokana, Levemir, Actos, Glimepiride, Amaryl, Novolin R, Mild Cognitive Impairment

Cost of Insulin Rises Threefold in Just a Decade: Study

Posted 5 Apr 2016 by Drugs.com

TUESDAY, April 5, 2016 – Americans with diabetes who rely on insulin to keep their blood sugar levels in check are facing sticker shock: A new study finds the price of insulin has tripled in only 10 years. Moreover, since 2010, per-person spending on insulin in the United States was more than spending on all other diabetes drugs, the study found. "The cost of insulin has risen rapidly over the last few years," said study senior author Philip Clarke, a professor of health economics at the University of Melbourne in Australia. Clarke added there should be an assessment to see whether this price hike is justifiable in terms of improved clinical outcomes. One reason for the price climb, he said, is a switch from human insulins to analog insulins, which cost more but may offer additional benefits. Also, doctors are more apt to prescribe insulin for people with type 2 diabetes now, Clarke ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Lantus, Diabetes, Type 1, Januvia, Glucophage, Novolog, Diabetic Neuropathy, Glipizide, Humalog, Insulin Resistance, Janumet, Byetta, Diabetic Nerve Damage, Glyburide, Saxenda, Bydureon, Lantus Solostar

FDA Medwatch Alert: SGLT2 Inhibitors: Drug Safety Communication - Labels to Include Warnings About Too Much Acid in the Blood and Serious Urinary Tract Infections

Posted 10 Dec 2015 by Drugs.com

ISSUE: An FDA safety review has resulted in adding warnings to the labels of a specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors about the risks of too much acid in the blood and of serious urinary tract infections. Both conditions can result in hospitalization. FDA issued a Drug Safety Communication in May 2015 warning about the risk of ketoacidosis with SGLT2 inhibitors and alerting that the Agency would continue to evaluate this safety issue. A review of the FDA Adverse Event Reporting System (FAERS) database from March 2013 to May 2015 identified 73 cases of ketoacidosis in patients with type 1 or type 2 diabetes treated with SGLT2 inhibitors (see the Drug Safety Communication Data Summary). Symptoms of ketoacidosis include nausea, vomiting, abdominal pain, tiredness, and trouble breathing. FDA also identified 19 cases of ... Read more

Related support groups: Diabetes, Type 2, Invokana, Farxiga, Jardiance, Canagliflozin, Dapagliflozin, Empagliflozin

New Diabetes Cases Among Americans Drop for First Time in Decades: CDC

Posted 1 Dec 2015 by Drugs.com

TUESDAY, Dec. 1, 2015 – In a sign that Americans may finally be turning the corner in the fight against diabetes – and possibly obesity – federal health statistics released Tuesday show that the number of new cases of diabetes has dropped for the first time in decades. The decline wasn't sudden or dramatic. But, the number of new diabetes cases went from 1.7 million in 2009 to 1.4 million in 2014, according to the U.S. Centers for Disease Control and Prevention. "It seems pretty clear that incidence rates have now actually started to drop. Initially it was a little surprising because I had become so used to seeing increases everywhere we looked," CDC researcher Edward Gregg told The New York Times. The proportion of Americans with diabetes is still twice what it was in the early 1990s. And not every racial group has made strides against the blood sugar disease, which is often ... Read more

Related support groups: Diabetes, Type 2, Obesity, Metformin, Weight Loss, Insulin, Victoza, Lantus, Januvia, Glucophage, Novolog, Glipizide, Humalog, Janumet, Byetta, Glyburide, Saxenda, Bydureon, Lantus Solostar, Invokana, Levemir

Too Many Seniors With Diabetes Are Overtreated, Study Suggests

Posted 29 Oct 2015 by Drugs.com

THURSDAY, Oct. 29, 2015 – When it comes to treating seniors with diabetes, new research suggests that doctors often don't cut back on medications, even when treatment goals are surpassed. The study found that when people had potentially dangerous low blood sugar levels, just 27 percent had their medicines decreased. And when blood pressure treatments lowered blood pressure levels too much, just 19 percent saw a reduction in their medications. "As people get older, the risks of overtreating become greater, and the benefits become shorter. We have to start emphasizing that more isn't always better," said study author Dr. Jeremy Sussman, an assistant professor of internal medicine at the University of Michigan in Ann Arbor and a primary care doctor at the Ann Arbor VA System. The findings were published online Oct. 26 in the journal JAMA Internal Medicine. Practice guidelines generally ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Lantus, Januvia, Glucophage, Novolog, Glipizide, Humalog, Janumet, Byetta, Glyburide, Saxenda, Bydureon, Lantus Solostar, Invokana, Levemir, Actos, Glimepiride

Tight Control of Type 2 Diabetes May Help Prevent Dementia

Posted 15 Sep 2015 by Drugs.com

TUESDAY, Sept. 15, 2015 – Keeping blood sugar levels in check may have a protective effect against dementia in people who have type 2 diabetes, new Swedish research suggests. "The positive association between [average blood sugar levels] and risk of dementia in fairly young patients with type 2 diabetes indicates a potential for prevention of dementia with improved blood sugar control," study author Dr. Aidin Rawshani, from the National Diabetes Register and Institute of Medicine in Gothenburg, Sweden, and colleagues wrote. However, the study wasn't able to definitively prove a cause-and-effect relationship between blood sugar levels and dementia; it was only able to show an association between these factors. The study included almost 350,000 people with type 2 diabetes. They were all registered in the Swedish National Diabetes Registry between January 2004 and December 2012. They had ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Dementia, Lantus, Alzheimer's Disease, Glucophage, Novolog, Glipizide, Humalog, Janumet, Glyburide, Lantus Solostar, Invokana, Levemir, Actos, Glimepiride, Amaryl, Novolin R, Mild Cognitive Impairment

FDA Medwatch Alert: Invokana and Invokamet (canagliflozin): Drug Safety Communication - New Information on Bone Fracture Risk and Decreased Bone Mineral Density

Posted 11 Sep 2015 by Drugs.com

ISSUE: FDA has strengthened the warning for the type 2 diabetes medicine canagliflozin (Invokana, Invokamet) related to the increased risk of bone fractures, and added new information about decreased bone mineral density. To address these safety concerns, FDA added a new WARNING AND PRECAUTION and revised the ADVERSE REACTIONS section of the Invokana and Invokamet drug labels. FDA is continuing to evaluate the risk of bone fractures with other drugs in the SGLT2 inhibitor class, including dapagliflozin (Farxiga, Xigduo XR) and empaglifozin (Jardiance, Glyxambi, Synjardy), to determine if additional label changes or studies are needed. Health care professionals and patients are urged to report side effects involving canagliflozin or other SGLT2 inhibitors to the FDA MedWatch program. BACKGROUND: Canagliflozin is a prescription medicine used with diet and exercise to lower blood sugar in ... Read more

Related support groups: Diabetes, Type 2, Invokana, Farxiga, Jardiance, Canagliflozin, Dapagliflozin, Invokamet, Empagliflozin, Canagliflozin/metformin

Health Tip: Diabetes Can Take a Toll on Teeth and Mouth

Posted 10 Aug 2015 by Drugs.com

-- Diabetes, especially when uncontrolled, can cause damage to your mouth and teeth. The Mouthhealthy.org website says possible effects of diabetes on the teeth and mouth include: Dry mouth, due to decreased saliva production. Increased risk of cavities due to less saliva. Gingivitis, characterized by bleeding, inflamed gums. Difficulty tasting food. Slower healing of mouth wounds. Increased risk of infection. Among diabetic children. teeth emerging earlier than expected. Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Oral and Dental Conditions, Xerostomia, Victoza, Lantus, Toothache, Diabetes, Type 1, Januvia, Glucophage, Novolog, Burning Mouth Syndrome, Diabetic Neuropathy, Glipizide, Humalog, Insulin Resistance, Janumet, Byetta, Aphthous Ulcer

People With Type 2 Diabetes Do Benefit From Blood Sugar Checks

Posted 5 Aug 2015 by Drugs.com

WEDNESDAY, Aug. 5, 2015 – Personalized blood sugar self-monitoring benefits people with type 2 diabetes even if they're not taking insulin, a new small study shows. Some experts have questioned the value of self-monitoring in this group, and many insurers – including Medicare – limit the reimbursement of blood sugar (glucose) testing strips to one a day for people with type 2 diabetes. This study included 11 people with type 2 diabetes who worked with the researchers to create personalized, structured self-monitoring blood glucose schedules. In most cases, self-monitoring twice a day was the most helpful in providing meaningful information about blood sugar levels. However, there was room for individualization based on a patient's type of lifestyle and needs. For example, a patient might check their blood sugar twice a day three days a week instead of once a day seven days a week, ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Lantus, Januvia, Glucophage, Novolog, Glipizide, Humalog, Janumet, Byetta, Glyburide, Saxenda, Bydureon, Lantus Solostar, Invokana, Levemir, Actos, Pre-Diabetes

FDA Issues Warning for Type 2 Diabetes Drugs

Posted 18 May 2015 by Drugs.com

MONDAY, May 18, 2015 – A certain class of type 2 diabetes drugs can lead to a life-threatening condition called ketoacidosis, the U.S. Food and Drug Administration warns. These prescription drugs are called sodium-glucose cotransporter-2 (SGLT2) inhibitors and include canagliflozin, dapagliflozin and empagliflozin. They work by prompting the kidneys to remove sugar in the blood through urine. The drugs are sold under the brand names: Invokana (canagliflozin), Invokamet (canagliflozin and metformin), Farxiga (dapagliflozin), Xigduo XR (dapagliflozin and metformin extended-release), Jardiance (empagliflozin), Glyxambi (empagliflozin and linagliptin). Between March 2013 and June 2014, the FDA received 20 reports of the drugs triggering ketoacidosis, in which levels of blood acids called ketones are too high. If untreated, ketoacidosis can lead to a diabetic coma or even death, according ... Read more

Related support groups: Diabetes, Type 2, Invokana, Diabetes Mellitus, Farxiga, Jardiance, Diabetic Ketoacidosis (DKA), Glyxambi, Diabetic Ketoacidosis (in DM Type II), Canagliflozin, Invokamet, Dapagliflozin, Canagliflozin/metformin, Empagliflozin/linagliptin, Empagliflozin, Diabetic Coma (in DM Type II), Dapagliflozin/metformin

FDA Medwatch Alert: SGLT2 inhibitors: Drug Safety Communication - FDA Warns Medicines May Result in a Serious Condition of Too Much Acid in the Blood

Posted 17 May 2015 by Drugs.com

ISSUE: FDA is warning that the type 2 diabetes medicines canagliflozin, dapagliflozin, and empagliflozin may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones that may require hospitalization. FDA is continuing to investigate this safety issue and will determine whether changes are needed in the prescribing information for this class of drugs, called sodium-glucose cotransporter-2 (SGLT2) inhibitors. BACKGROUND: SGLT2 inhibitors are a class of prescription medicines that are FDA-approved for use with diet and exercise to lower blood sugar in adults with type 2 diabetes. When untreated, type 2 diabetes can lead to serious problems, including blindness, nerve and kidney damage, and heart disease. SGLT2 inhibitors lower blood sugar by causing the kidneys to remove sugar from the body through the urine. These medicines are available ... Read more

Related support groups: Diabetes, Type 2, Invokana, Farxiga, Jardiance, Glyxambi, Canagliflozin, Dapagliflozin, Invokamet, Empagliflozin/linagliptin, Empagliflozin, Dapagliflozin/metformin, Canagliflozin/metformin

Ask a Question

Further Information

Related Condition Support Groups

Diabetes, Type 2

Jardiance Patient Information at Drugs.com